Reading ABBV? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track ABBV free→Reading ABBV? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track ABBV free→NYSEHealth CareDrug Manufacturers - GeneralSnapshot 2026-06-12
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
Recent financial performance is strong, but management's recent track record has been unsteady, with frequent disruptive corporate changes. Earnings quality is robust, and risk is low, while the sector backdrop is a headwind. Peer multiples imply a price about 4% below where it trades (it looks expensive on this basis); the read is full. If ABBV reverses and cuts guidance after recently raising, that could lead to a credibility hit.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 7 valuation methods, at three horizons. Current price $227.73. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $228 ABBV trades at 22× p/e — 1.4× the 16× p/e peer median, and above its own 17× history. The market is re-rating it beyond its own range; our $222 fair value is medium-confidence here. Analysts: $235–$299. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
The market is pricing in roughly 3% near-term growth, below our forecast of about 14%. This describes what's priced in, not a forecast of the move.
Only a turbulent sector regime (Heating) — not the full expensive x weak x turbulent stack.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated strong grew net income 59% of the time over the next year (vs 52% for the rest of the cohort, n=2344).
Over the trailing year it converted 5.84x of net income into operating cash flow. Historically, Health Care names rated robust grew net income 60% of the time over the next year (vs 48% for the rest of the cohort, n=1703).
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity.
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
EPS estimate $3.76 → $3.77 (+0.1% / 30d). 10 raised, 7 cut, 21 covering analysts.
0 upgrades, 0 downgrades / 30d, 2 maintained. 75% of analysts rate Buy.
1 PT revisions / 30d. Avg target 10.8% above current price.
Transition story with positive analyst positioning (often a turnaround setup).
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
On a typical day, $10k can swing ±$99.
How much price usually moves either way.
On a bad day, this stock has moved -$237.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $1,731.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
Valuation changed. It rose to a full label from fair. Risk remained low. Management became volatile. The sector backdrop is a headwind.
as of 2026-06-12
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: Another earnings miss may show ongoing problems for AbbVie’s money and growth.
Confirms:Q1 2026 earnings report shows adjusted EPS below $2.71.
Disproves:Q1 2026 earnings report shows adjusted EPS above $2.71.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for ABBV yet.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
. 104 The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ABBVIE INC. Date: April 29, 2026 By: /s/ Scott T. Reents Scott T. Reents Executive Vice President, Chief Financial Officer
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
$235.00 – $299.00 (median $268.50) · 10 analysts · as of 2026-05-15
Looks more expensive than peers.
Richer than its own typical valuation.
Trailing four: 2025-Q1, 2025-Q2, 2025-Q3, 2026-Q1
A side-by-side read on sector standing, valuation, and risk versus Biotechnology.
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
ABBV AbbVie | Above typical Show detailsSector percentile: 79 of 100 | fair | low |
AMGN Amgen | Above typical Show detailsSector percentile: 75 of 100 | full | moderate |
GILD Gilead Sciences | Above typical Show detailsSector percentile: 96 of 100 | fair | moderate |
VRTX Vertex Pharmaceuticals | Above typical Show detailsSector percentile: 82 of 100 | expensive | moderate |
REGN Regeneron Pharmaceuticals | Above typical Show detailsSector percentile: 85 of 100 | fair | moderate |
10 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated volatile grew net income 43% of the time over the next year (vs 57% for the rest of the cohort, n=600).
Not investment advice. As of 2026-06-12.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-12.
Met or beat guidance 100% of the last 8 guided quarters · 4.0% avg surprise
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
AbbVie aims to increase its EPS guidance for the fiscal year 2026.
AbbVie has announced a share buyback program as part of its capital allocation strategy.
AbbVie has issued debt to raise capital for strategic initiatives.
Why it matters: A share buyback may show that management trusts AbbVie's financial health. It could help the stock price.
Confirms:AbbVie announces a share buyback program.
Disproves:No announcement of a share buyback by the next earnings call.
Why it matters: Issuing debt may show AbbVie's plan to fund growth and manage capital.
Confirms one read:AbbVie announces a debt issuance to fund capital projects.
Confirms the other:No announcement of debt issuance by the next earnings call.
Results of Operations and Financial Condition Reported GAAP earnings and adjusted non-GAAP earnings for the first quarter of 2026 are expected to include acquired IPR&D and milestones expense of $744 million on a pre-tax basis, representing an unfavorable impact of $0.41 to both GAAP diluted earnings per share and adjusted non-GAAP diluted earnings per share. Results for the quarter ended March 31, 2026 have not been finalized and are subject to our financial statement closing procedures. The…
Other Events. On March 4, 2026, AbbVie Inc. (“ AbbVie ”) completed its previously announced underwritten public offering (the “ Notes Offering ”) of $750,000,000 aggregate principal amount of its senior floating rate notes due 2028 (the “ Floating Rate Notes ”), $1,500,000,000 aggregate principal amount of its 3.775% senior notes due 2028 (the “ 2028 Notes ”), $1,250,000,000 aggregate principal amount of its 4.125% senior notes due 2031 (the “ 2031 Notes ”), $1,250,000,000 aggregate principal…
Other Events. On February 24, 2026, AbbVie Inc. (“ AbbVie ”) entered into an underwriting agreement (the “ Underwriting Agreement ”) with J.P. Morgan Securities LLC, BofA Securities, Inc., Morgan Stanley & Co. LLC and Wells Fargo Securities, LLC, acting for themselves and as representatives of the several underwriters named in Schedule II therein (collectively, the “ Underwriters ”), pursuant to which AbbVie agreed to issue and sell to the Underwriters $750,000,000 aggregate principal amount…
. 104 The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ABBVIE INC. Date: February 4, 2026 By: /s/ Scott T. Reents Scott T. Reents Executive Vice President, Chief Financial Officer